Dr. SangYoul Yun is a Korean Board-Certified Dermatologist with fellowship affiliation with the American Academy of Dermatology (AAD International Fellow), membership in the American Society for Laser Medicine and Surgery (ASLMS), and active membership in nine Korean dermatology societies. He previously served as a senior dermatologist at Banobagi.
Baricitinib, ritlecitinib, and deuruxolitinib are FDA approved for severe alopecia areata. Compare age limits, trials, boxed warnings, and evidence gaps.
Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.
Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.
The FDA received reports of serious complications with certain RF microneedling uses in 2025. Learn what was reported, remains unknown, and how needling differs.
Lebrikizumab and nemolizumab target different atopic dermatitis pathways. Compare their FDA labels, phase 3 designs, safety limits, and evidence gaps.
Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.
Hypochlorous acid face spray is popular, but human evidence mainly comes from wound care. See what HOCl may do, what remains unproven, and safety limits.
Mechanism, efficacy data, downtime, and the post-inflammatory hyperpigmentation risk that dominates ablative fractional CO2 resurfacing for atrophic acne scars, with a focus on darker and Asian skin.
How microfocused ultrasound, monopolar radiofrequency, and RF microneedling differ for skin tightening, and how clinicians choose the right energy-based option.
Erythema nodosum causes tender red nodules on the shins and often signals an underlying trigger. What causes it, how it is diagnosed, and how it is treated.
Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.
What solar lentigines are, how they differ from other pigmented spots, and what the evidence supports for lasers, IPL, cryotherapy, peels, and topical agents.
What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.
How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.
What the evidence supports for male androgenetic alopecia: minoxidil, finasteride and dutasteride, adjunct options, and realistic expectations on results and risks.
A phenotype-based guide to rosacea: how flushing, persistent redness, papules and pustules, visible vessels, and eye involvement are treated, and why trigger control matters.
How topical retinoids work, how prescription tretinoin compares with retinaldehyde, retinol, and adapalene, and how to choose a tolerable option for aging or acne-prone skin.
How clinicians classify atrophic acne scars (ice-pick, boxcar, rolling) and what the evidence supports for subcision, fractional lasers, microneedling RF, and fillers.
What the evidence supports for treating common and plantar warts, why salicylic acid and cryotherapy are first-line, and when persistent warts need a different approach.
The World Federation for Ultrasound in Medicine and Biology (WFUMB) released 24 consensus recommendations standardizing dermatologic ultrasound for aesthetic procedures — what changed and what it means for practice.
Do exosome skin treatments work? Reviews find encouraging short-term signals, but mostly non-randomized studies and unresolved long-term safety gaps remain.
Why oral minoxidil at low dose has become a workhorse for female pattern hair loss, how Korean dermatology practices approach diagnosis and combination therapy, and what the evidence supports.
After rapid weight loss on GLP-1 drugs, loose skin on the abdomen, arms, and thighs is common. What the evidence says about energy-based tightening, biostimulators, timing, and when surgery is the realistic option.
Why some patients on semaglutide or tirzepatide notice hair shedding, what pharmacovigilance and review data show, the likely telogen effluvium mechanism, and how it is managed.
What 41 studies show about RF microneedling efficacy, how devices differ, and why the FDA's 2025 serious-complication reports limit broad safety claims.
Why adult-onset acne in women is often hormonally driven, how it differs from adolescent acne, and what the evidence supports for combined oral contraceptives, spironolactone, and topical therapy.
Why GLP-1 receptor agonists cause facial volume loss, severity predictors, and the published multimodal restoration approaches in 2026.
Why visible light, not just UV, drives melasma and post-inflammatory pigmentation — and what tinted iron oxide sunscreens add to a summer skin care routine in 2026.
What polynucleotide injectables do, what the systematic review data shows, how they compare with HA boosters, adverse events, and patient selection.
Mechanism of collagen induction, expected timeline, reconstitution evidence, recognized complications, and patient selection for PLLA.
Mechanism, timeline, comparator data vs MFU-V, adverse events, and patient selection for monopolar radiofrequency facial tightening.
MFU-V means microfocused ultrasound with visualization in aesthetic medicine. Review skin-tightening results, safety, timelines, and patient selection.
Evidence for FDA-approved hydroquinone + tretinoin + fluocinolone for melasma — efficacy vs monotherapy, adverse effects, and adjunctive options.
What patients should ask and clinicians should disclose before MFU-V, radiofrequency, or combination skin tightening — checklist + red flags.